Regular Aspirin Use Associates With Lower Risk of Colorectal Cancers With Low Numbers of Tumor-Infiltrating Lymphocytes

Gastroenterology

Volumn 151, Issue 5, 2016, Pages 879-892.e4

  Cao, Yin ^a,b   Nishihara, Reiko ^a,c   Qian, Zhi Rong ^c   Song, Mingyang ^a,b   Mima, Kosuke ^c   Inamura, Kentaro ^d   Nowak, Jonathan A ^e   Drew, David A ^b   Lochhead, Paul ^b   Nosho, Katsuhiko ^f   Morikawa, Teppei ^g   Zhang, Xuehong ^e   Wu, Kana ^a   Wang, Molin ^a   Garrett, Wendy S ^a,h   Giovannucci, Edward L ^a,e   Fuchs, Charles S ^c,e   Chan, Andrew T ^b,e   Ogino, Shuji ^a,c,e  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d CANCER INSTITUTE   (Japan)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^h BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

Immunoprevention; Molecular Pathological Epidemiology; NSAID; Pharmacoepidemiology

Indexed keywords

ACETYLSALICYLIC ACID; B RAF KINASE; CD45RO ANTIGEN; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CANCER RISK; CD3+ T LYMPHOCYTE; CD45RO+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLORECTAL CANCER; COLORECTAL CARCINOMA; COMPUTER ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DOSE RESPONSE; FEMALE; FOLLOW UP; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LEUKOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; QUESTIONNAIRE; RISK ASSESSMENT; RISK REDUCTION; T LYMPHOCYTE; TREATMENT DURATION; TUMOR ASSOCIATED LEUKOCYTE; UNITED STATES; ADENOCARCINOMA; COLORECTAL NEOPLASMS; IMMUNOLOGY; LYMPHOCYTE COUNT; MIDDLE AGED; PROSPECTIVE STUDY; RISK; TUMOR MICROENVIRONMENT;

ADENOCARCINOMA; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK; TUMOR MICROENVIRONMENT;

EID: 84994850679     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.07.030     Document Type: Article

References (51)

1. 1 Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J Clin 66 (2016), 7–30.
2. 2 Cuzick, J., Thorat, M.A., Bosetti, C., et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 26 (2015), 47–57.
3. 3 Cao, Y., Nishihara, R., Wu, K., et al. Population-wide Impact of long-term use of aspirin and the risk for cancer. JAMA Oncol 2 (2016), 762–769.
4. 4 Thun, M.J., Jacobs, E.J., Patrono, C., The role of aspirin in cancer prevention. Nat Rev Clin Oncol 9 (2012), 259–267.
5. 5 Drew, D.A., Cao, Y., Chan, A.T., Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer 16 (2016), 173–186.
6. 6 Umar, A., Steele, V.E., Menter, D.G., et al. Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention. Semin Oncol 43 (2016), 65–77.
7. 7 Xia, D., Wang, D., Kim, S.H., et al. Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat Med 18 (2012), 224–226.
8. 8 Galon, J., Mlecnik, B., Bindea, G., et al. Towards the introduction of the Immunoscore in the classification of malignant tumors. J Pathol 232 (2014), 199–209.
9. 9 Palmqvist, R., Wikberg, M.L., Ling, A., et al. The association of immune cell infiltration and prognosis in colorectal cancer. Curr Colorectal Cancer Rep 9 (2013), 372–379.
10. 10 Joyce, J.A., Fearon, D.T., T cell exclusion, immune privilege, and the tumor microenvironment. Science 348 (2015), 74–80.
11. 11 Fridman, W.H., Pages, F., Sautes-Fridman, C., et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12 (2012), 298–306.
12. 12 Chan, A.T., Ogino, S., Fuchs, C.S., Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356 (2007), 2131–2142.
13. 13 Gobel, C., Breitenbuecher, F., Kalkavan, H., et al. Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity. Cell Death Dis, 5, 2014, e1568.
14. 14 Burkholder, B., Huang, R.Y., Burgess, R., et al. Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta 1845 (2014), 182–201.
15. 15 Zelenay, S., van der Veen, A.G., Bottcher, J.P., et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162 (2015), 1257–1270.
16. 16 Rooney, M.S., Shukla, S.A., Wu, C.J., et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160 (2015), 48–61.
17. 17 Ogino, S., Nosho, K., Irahara, N., et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 15 (2009), 6412–6420.
18. 18 Nishihara, R., Lochhead, P., Kuchiba, A., Jung, S., et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA 309 (2013), 2563–2571.
19. 19 Nosho, K., Baba, Y., Tanaka, N., et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 222 (2010), 350–366.
20. 20 Wang, M., Spiegelman, D., Kuchiba, A., et al. Statistical methods for studying disease subtype heterogeneity. Stat Med 35 (2016), 782–800.
21. 21 McCullough, M.L., Feskanich, D., Stampfer, M.J., et al. Diet quality and major chronic disease risk in men and women: moving toward improved dietary guidance. Am J Clin Nutr 76 (2002), 1261–1271.
22. 22 Chiuve, S.E., Fung, T.T., Rimm, E.B., et al. Alternative dietary indices both strongly predict risk of chronic disease. J Nutr 142 (2012), 1009–1018.
23. 23 Marzbani, E., Inatsuka, C., Lu, H.L., et al. The invisible arm of immunity in common cancer chemoprevention agents. Cancer Prev Res 6 (2013), 764–773.
24. 24 Kensler, T.W., Spira, A., Garber, J.E., et al. Transforming cancer prevention through precision medicine and immune-oncology. Cancer Prev Res (Phila) 9 (2016), 2–10.
25. 25 Hussain, M., Javeed, A., Ashraf, M., et al. Aspirin and immune system. Int Immunopharmacol 12 (2012), 10–20.
26. 26 Chia, W.K., Ali, R., Toh, H.C., Aspirin as adjuvant therapy for colorectal cancer-reinterpreting paradigms. Nat Rev Clin Oncol 9 (2012), 561–570.
27. 27 Tougeron, D., Sha, D., Manthravadi, S., et al. Aspirin and colorectal cancer: back to the future. Clin Cancer Res 20 (2014), 1087–1094.
28. 28 Li, P.W., Wu, H., Zhang, H.H., et al. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. Gut 64 (2015), 1419–1425.
29. 29 Roy, H.K., Turzhitsky, V., Wali, R., et al. Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin. Gut, 2015 Epub ahead of print.
30. 30 Matasic, R., Dietz, A.B., Vuk-Pavlovic, S., Cyclooxygenase-independent inhibition of dendritic cell maturation by aspirin. Immunology 101 (2000), 53–60.
31. 31 Negrotto, S., Malaver, E., Alvarez, M.E., et al. Aspirin and salicylate suppress polymorphonuclear apoptosis delay mediated by proinflammatory stimuli. J Pharmacol Exp Ther 319 (2006), 972–979.
32. 32 El Kebir, D., Jozsef, L., Khreiss, T., et al. Aspirin-triggered lipoxins override the apoptosis-delaying action of serum amyloid A in human neutrophils: a novel mechanism for resolution of inflammation. J Immunol 179 (2007), 616–622.
33. 33 Gerli, R., Gresele, P., Bistoni, O., et al. Salicylates inhibit T cell adhesion on endothelium under nonstatic conditions: induction of L-selectin shedding by a tyrosine kinase-dependent mechanism. J Immunol 166 (2001), 832–840.
34. 34 Gerli, R., Paolucci, C., Gresele, P., et al. Salicylates inhibit adhesion and transmigration of T lymphocytes by preventing integrin activation induced by contact with endothelial cells. Blood 92 (1998), 2389–2398.
35. 35 Okugawa, Y., Grady, W.M., Goel, A., Epigenetic alterations in colorectal cancer: emerging biomarkers. Gastroenterology 149 (2015), 1204–1225.
36. 36 Colussi, D., Brandi, G., Bazzoli, F., et al. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 14 (2013), 16365–16385.
37. 37 Carethers, J.M., Jung, B.H., Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology 149 (2015), 1177–1190.
38. 38 Saeterdal, I., Bjorheim, J., Lislerud, K., et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A 98 (2001), 13255–13260.
39. 39 Schwitalle, Y., Kloor, M., Eiermann, S., et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 134 (2008), 988–997.
40. 40 Brown, S.D., Warren, R.L., Gibb, E.A., et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 24 (2014), 743–750.
41. 41 Boissiere-Michot, F., Lazennec, G., Frugier, H., et al. Characterization of an adaptive immune response in microsatellite-instable colorectal cancer. Oncoimmunology, 3, 2014, e29256.
42. 42 Le, D.T., Uram, J.N., Wang, H., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 (2015), 2509–2520.
43. 43 Dahlin, A.M., Henriksson, M.L., Van Guelpen, B., et al. Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod Pathol 24 (2011), 671–682.
44. 44 Llosa, N.J., Cruise, M., Tam, A., et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 5 (2015), 43–51.
45. 45 Ogino, S., Galon, J., Fuchs, C.S., et al. Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 8 (2011), 711–719.
46. 46 Lal, N., Beggs, A.D., Willcox, B.E., et al. An immunogenomic stratification of colorectal cancer: implications for development of targeted immunotherapy. Oncoimmunology, 4, 2015, e976052.
47. 47 Galon, J., Costes, A., Sanchez-Cabo, F., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006), 1960–1964.
48. 48 Di Caro, G., Marchesi, F., Laghi, L., et al. Immune cells: plastic players along colorectal cancer progression. J Cell Mol Med 17 (2013), 1088–1095.
49. 49 Mei, Z., Liu, Y., Liu, C., et al. Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer 110 (2014), 1595–1605.
50. 50 Reissfelder, C., Stamova, S., Gossmann, C., et al. Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis. J Clin Invest 125 (2015), 739–751.
51. 51 Koshiol, J., Lin, S.W., Can tissue-based immune markers be used for studying the natural history of cancer?. Ann Epidemiol 22 (2012), 520–530.